Medication info
Huglyia Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Huglyia Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablets
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202102407 · Approved 2021.03.17 · Insurance code 670609010

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes in conjunction with diet and exercise therapy. It can also be used alone, but if blood sugar control is inadequate, it can be administered in combination with other diabetes medications such as Metformin, Sulfonylureas, Thiazolidinediones, or Insulin. Adding this medication can improve blood sugar control, especially when existing treatments are insufficient. It is a medication that aids patient-customized blood sugar management through various treatment options and combinations.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause allergic reactions; therefore, if symptoms such as skin rash or difficulty breathing occur after administration, discontinue use immediately and consult a doctor. While taking this medication, symptoms of pancreatitis, such as severe abdominal pain, vomiting, and fever may occur, so if these symptoms appear, immediately discontinue the medication and visit a hospital. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered to those with allergies to this medication or its components. Patients with decreased kidney function need to adjust the dosage of this medication, so appropriate dosing must be determined through kidney function tests. When using this medication with other blood sugar-lowering agents, particularly insulin or sulfonylureas, the risk of hypoglycemia may increase; thus, careful monitoring of blood sugar levels is required, and dosage adjustments should be considered as needed. In some patients, severe joint pain or skin conditions may occur; if such symptoms arise, consult a physician immediately to determine whether to discontinue the medication. Pregnant or breastfeeding women are advised not to use this medication, and safety in pediatric patients has not been sufficiently established. Elderly patients are more likely to have impaired kidney function, so kidney function should be monitored regularly, and dosage adjustments made when administering this medication. In case of overdose, general treatment such as removing the medication from the gastrointestinal tract should be performed, and if necessary, hemodialysis may be carried out to remove the drug. This medication has minimal interactions with other drugs, but it is advisable to consult a physician or pharmacist when taking certain medications.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, joint pain accompanied by severe and disability, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased blood triglycerides, gastritis, elevated low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure, preferably at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablets

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.